Company: LGNZZ
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0000886163-25-000025
Chunk: 63

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 63
---
174,066 |     |                     |  7,807 |     |                           |   761,962 |
| Andrew Reardon       |     |                      | 13,500 |     |                              |   483,596 |     |                     |  4,751 |     |                           |   427,632 |
| Matthew Korenberg(3) |     |                      | 46,779 |     |                              | 2,586,207 |     |                     | 57,539 |     |                           | 5,521,861 |

(1) Computed by multiplying the (a) the closing market price of our common stock on the exercise date, less the option exercise price per share, multiplied by (b) the number of shares acquired upon exercise of the option.

(2) Computed by multiplying the closing market price of our common stock on the vesting date by the number of RSUs or PSUs subject to such award vesting on the applicable vesting date.

(3) Mr. Korenberg resigned from his role as President and Chief Operating Officer effective October 15, 2024.

### POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL
The following table summarizes potential change in control and severance payments to each named executive officer as of December 31, 2024. The three right-hand columns describe the payments that would apply in three different potential scenarios—a termination without cause prior to a change in control or more than 24 months following a change in control (Mr. Davis would also be entitled to such benefits if he resigned for good reason at such times); a change in control without a termination of employment; or a termination of employment as a result of the named executive officer’s resignation for good

50

reason or termination of employment by us other than for cause, in each case within 24 months following a change in control. The table assumes that the termination or change in control occurred on December 31, 2024. For purposes of estimating the value of accelerated equity awards to be received in the event of a termination of employment or change in control, we have assumed a price per share of our common stock of $107.15, which represents the closing market price of our common stock as reported on the Nasdaq Global Market on December 31, 2024, the last trading day of 2024. All cash severance benefits will be paid in a lump sum.

| Name           |     | Benefit                  |     |